Download Image
    
Share
  
Post
Defibrotide for COVID-19
1 study with 150 patients
Hospital Icon Control
Hospital Icon Defibrotide Serious Outcome Risk
No significant improvements are seen in meta-analysis to date.
COVID-19 Defibrotide studies. Jun 2026. c19early.org
0 0.5 1 1.5+ All studies -23% Mortality -23% Hospitalization -18% RCTs -23% Late -23% Favorsdefibrotide Favorscontrol
Recent:
Ruggeri
Jara Rubio.
May 12
 Jara Rubio et al., European Journal of Haematology, doi:10.1111/ejh.70214 Phase IIB, Randomized, Double‐Blind, Placebo‐Controlled Clinical Trial of Intravenous Defibrotide for the Prevention and Treatment of Respiratory Distress and Cytokine Release Syndrome in COVID-19
23% higher mortality (p=0.56), 200% higher progression (p=0.14), no change in ICU admission (p=1), and 18% longer hospitalization (p=0.41). RCT 150 hospitalized COVID-19 patients with respiratory failure showing no significant benefit with continuous IV defibrotide versus placebo.
May 23
2024
 Ruggeri et al., Haematologica, doi:10.3324/haematol.2024.285345 Use of defibrotide in COVID-19 pneumonia: comparison of a phase II study and a matched real-world cohort control
22% lower mortality (p=0.25) and 29% lower progression (p=0.14). Phase II trial of 48 hospitalized COVID-19 pneumonia patients receiving non-invasive ventilation, compared against a retrospective matched cohort of 153 controls receiving standard of care, showing a trend towards benefit with defibrotide..